Efficient, Low-Cost Nucleofection of Passaged Chondrocytes
Authors:
Open Access
- 19 October 2015
- journal article
- research article
- Published by SAGE Publications in CARTILAGE
- Vol. 7 (1) , 82-91
Abstract
Nucleofection of chondrocytes has been shown to be an adequate method of transfection. Using Amaxa’s nucleofection system, transfection efficiencies up to 89% were achievable for vector (pmaxGFP) and 98% for siRNA (siGLO) into passaged chondrocytes. However, such methods rely on costly commercial kits with proprietary reagents limiting its use in basic science labs and in clinical translation. Bovine-passaged chondrocytes were plated in serum reduced media conditionsand then nucleofected using various in laboratory-produced buffers. Cell attachment, confluency, viability, and transfection efficiency was assessed following nucleofection. For each parameter the buffers were scored and a final rank for each buffer was determined. Buffer denoted as 1M resulted in no significant difference for cell attachment, confluency, and viability as compared to non-nucleofected controls. Nucleofection in 1M buffer, in the absence of DNA vectors, resulted in increased col2, ki67, ccnd1 mRNA levels, and decreased col1 mRNA levels at 4 days of culture. Flow cytometry revealed that the transfection efficiency of 1M buffer was comparable to that obtained using the Amaxa commercial kit. siRNA designed against lamin A/C resulted in an average reduction of lamin A and C proteins to 19% and 8% of control levels, respectively. This study identifies a cost-effective, efficient method of nonviral nucleofection of bovine-passaged chondrocytes using known buffer formulations. Human-passaged chondrocytes could also be successfully nucleofected in 1M buffer. Thus this method should facilitate cost-efficient gene targeting of cells used for articular cartilage repair in a research setting.Keywords
This publication has 26 references indexed in Scilit:
- Suppression of dedifferentiation and hypertrophy in canine chondrocytes through lentiviral vector expression of Sox9 and induced pluripotency stem cell factorsBiotechnology Letters, 2015
- Chitosan-Graft-Polyethylenimine/DNA Nanoparticles as Novel Non-Viral Gene Delivery Vectors Targeting OsteoarthritisPLOS ONE, 2014
- Control of Collagen Production in Mouse Chondrocytes by Using a Combination of Bone Morphogenetic Protein-2 and Small Interfering RNA Targeting Col1a1 for Hydrogel-Based Tissue-Engineered CartilageTissue Engineering Part C: Methods, 2013
- Enhanced cartilage formation by inhibiting cathepsin K expression in chondrocytes expanded in vitroBiomaterials, 2012
- Competitive DNA transfection formulation via electroporation for human adipose stem cells and mesenchymal stem cellsBiological Procedures Online, 2012
- Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patientsCytotherapy, 2012
- Efficient non-viral transfection of primary human adult chondrocytes in a high-throughput formatOsteoarthritis and Cartilage, 2009
- In vitro expression of erythropoietin by transfected human mesenchymal stromal cellsCytotherapy, 2008
- Regulation of SOX9 mRNA in Human Articular Chondrocytes Involving p38 MAPK Activation and mRNA StabilizationJournal of Biological Chemistry, 2006
- Stimulation of chondrocytes in vitro by gene transfer with plasmids coding for epidermal growth factor (hEGF) and basic fibroblast growth factor (bFGF)Cytotherapy, 2005